Back in July, the popular blood pressure drug valsartan was voluntarily recalled after it was discovered to contain a cancer-causing ingredient, N-nitrosodimethylamine (NMDA). NDMA is a human carcinogen which is found in liquid rocket fuels, additives for lubricants, and other substances. At that time, the FDA believed the impurity was related to changes in the way that the drug was manufactured.
Just last week, the federal government found another suspected carcinogen in valsartan. The suspected carcinogen is called N-nitrosodiethylamine (NDEA). NDEA is found in tobacco smoke. It was discovered in three lots of valsartan drugs that were made by Torrent Pharmaceuticals. It also found NDEA in several batches of the drug that were made by another manufacturer. The FDA says it is continuing to test all valsartan products, and that if any more contaminated products were found, it would work with companies to remove all the products from the market. It is also examining the risks that NDEA may pose to patients.
The FDA says that even if a valsartan product has been recalled, patients should continue taking it until their doctor or pharmacist gives them a different medication or a different treatment option. Not all valsartan products contain NDMA or NDEA, and doctors may also be able to prescribe a different medication that can treat the same condition.
Although most prescription drugs that are manufactured in the U.S. are safe for their intended uses, some are not. Many may be incorrectly manufactured, may have serious side effects, or may not have been thoroughly tested before being released on the market. If you or a loved one has suffered from unexpected complications from a prescription drug, you should speak with an attorney. Call the prescription drug defect attorneys at Kennedy Hodges at 855-947-0707. We can help. Call to learn more, or visit us on Twitter.